The novel coronavirus (Covid-19) has been wreaking global havoc over the past few months. It has pushed millions of people across the world into lockdown in their homes, forced many businesses to close and has tragically killed over 82,000 people globally at the time of writing.

Although the pharma industry has been invigorated to fight against Covid-19 with drugs and vaccines, the industry’s work has also been damaged by the pandemic, primarily through the disruption of supply chains.

This situation has the potential to cause drug shortages of critical medicines, as well as undermine necessary clinical research, which could, in the long run, push pharma companies to seek to not rely so much on one country for its APIs.

Read the full story here.